ArticleDoklady. Biochemistry and biophysics2022
Basic Fibroblast Growth Factor Blockade Leads to Distinct Cellular Responses in Melanoma B16 Cells.
Article in Doklady. Biochemistry and biophysics, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed, 3 citations in OpenAlex.
- Melanoma treatment in the era of nanotechnology and precision medicine.Journal of nanobiotechnology · 2025Review
- Dichotomic Role of Low-Concentration EGCG in the Oxaliplatin Sensitivity of Colorectal Cancer Cells.Doklady. Biochemistry and biophysics · 2024Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Although bFGF is highly expressed in the melanoma tissues, its specific role in melanoma progression is still not completely clarified. Here, we investigated the consequent cellular responses in melanoma B16 cells after bFGF blocking by using a neutralizing monoclonal antibody (mAb). Results showed that bFGF mAb concentration dependent inhibited tumor cell growth. Meanwhile, cell viability suppression was accompanied by reduced levels of proangiogenic factors in low-concentration bFGF mAb-treated cancer cells and increased levels of proangiogenic factors in high-concentration bFGF mAb-treated cells. Furthermore, low-concentration bFGF mAb induced autophagy but not apoptosis; conversely, high-concentration bFGF mAb led to activation of autophagy and apoptosis. Finally, we found that different degrees of bFGF blockade-induced autophagy play distinct roles in promoting cell survival and cell death. Our findings revealed different adaptive responses to bFGF blockade in melanoma cells, which should be taken seriously when developing bFGF-targeting agents for melanoma treatment.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.